Objective: The objective of this study is to assess the efficacy of oral fluoxetine therapy in improving the visual function of amblyopic patients aged between 10 and 40 years old.
Methods: In this double-blinded, randomized, controlled trial (IRCT2016052428046N1; registered retrospectively), 40 eligible participants with anisometropic or mixed amblyopia were randomly assigned to either fluoxetine or placebo groups. Participants with anisometropia and logMAR best spectacle-corrected visual acuity (BSCVA) worse than 0.2 logMAR in the amblyopic eye or at least a two-line of difference in the BSCVA between the fellow eyes were included. Participants with significant ocular or systemic diseases were excluded. In both groups, the better eye of each patient was patched for 4-6 h a day during the study period. Participants in the treatment group were treated with oral fluoxetine for 3 months. Change in the Snellen BSCVA (after 3 months) was regarded as the primary outcome measure.
Results: Data from 20 participants in the fluoxetine group and 15 participants from the placebo group were analyzed (aged 11-37 years). The magnitude of improvement in visual acuity (from baseline to 3 months after treatment) was significantly higher in the fluoxetine group (0.240 ± 0.068 logMAR; 2.4 line-gain) compared with the control group (0.120 ± 0.086 logMAR; 1.2 line-gain).
Conclusions: This study suggests beneficial effects of fluoxetine in the management of adult and adolescent amblyopia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707246 | PMC |
| http://dx.doi.org/10.1038/s41433-019-0360-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Influence of Fluoxetine on the Sensorimotor Function of the Sciatic Nerve in Wistar Rats after Axonotmesis: An Experimental Animal Model.
J Oral Maxillofac Surg
December 2024
PhD Adjunct Professor, in Oral and Maxillofacial Surgery, School of Dentistry, University of Pernambuco - UPE, Recife, Pernambuco, Brazil. Electronic address:
Background: Fluoxetine, a serotonin reuptake inhibitor antidepressant, raises extracellular serotonin levels and promotes angiogenesis and neurogenesis. Numerous animal models have shown its beneficial effects on recovery from peripheral nerve injury.
Purpose: The primary objective of this study was to analyze the influence of fluoxetine on the sensory-motor function recovery of the sciatic nerve in Wistar rats after axonotmesis.
Luteolin Exhibits Anxiolytic and Antidepressant Potential in Parkinson's Disease Rat: Antioxidant and Anti-Inflammatory Effects.
Rejuvenation Res
December 2024
Department of Neurology, Jinan Central Hospital, Shandong University, Jinan City, People's Republic of China.
Parkinson's disease (PD) is accompanied by a complex array of nonmotor and motor manifestations. The exploration of anti-inflammatory and antioxidant active ingredient as potential therapeutic interventions in PD-associated mood alterations has gained significant attention. This study aimed to assess the antidepressant and anxiolytic properties of luteolin (LTN), a potent antioxidant and anti-inflammatory component, using a 6-hydroxydopamine (6-OHDA)-induced animal model of PD.
View Article and Find Full Text PDFCan fluoxetine influence orthodontic tooth movement? A systematic review and meta-analysis of studies on animal models.
Int Orthod
December 2024
Department of Periodontics and Endodontics, School of Dental Medicine, Stony Brook University, Stony Brook, NY, 11794, United States.
Introduction: Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine adversely affect bone mineral density (BMD) and turnover, thereby increasing the risk of fractures. The objective of the present systematic review and meta-analysis was to evaluate studies on animal models that assessed whether fluoxetine can influence orthodontic tooth movement (OTM).
Material And Methods: Indexed databases (PubMed/Medline, EMBASE, Cochrane Library, Scopus and ISI Web of Knowledge) and Google Scholar were searched without time and language barriers up to and including June 2024.
The unique role of fluoxetine in alleviating depression and anxiety by regulating gut microbiota and the expression of vagus nerve-mediated serotonin and melanocortin-4 receptors.
Biomed Pharmacother
January 2025
School of Pharmacy and Institute of New Drug Development, Jeonbuk National University Jeonju 54896, Republic of Korea. Electronic address:
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) widely used for depression, but its potential effects on gut microbiota regulation and vagus nerve-mediated serotonin receptor expression have not been well studied. We investigated changes in the gut microbiome regulated by fluoxetine and vagus nerve-mediated expression of several serotonin (5-HT) receptor types associated with anxiety and depression. Oral administration of fluoxetine alleviated lipopolysaccharide (LPS)-induced depressive and anxiety behaviors, increased 5-HT1A, 2 C, and melanocortin 4 (MC4) receptor expression, and the composition of Lactobacillus in mice's gut microbiome.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!